SCHEMBL3659639

SCHEMBL3659639

O=C(O)CCCCCCCCCCOc1ccc(C(=O)O)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.58
PPARD Q03181 1/20 0.55
MAOB P27338 9/20 0.51
ALDH2 P05091 6/20 0.50
MAOA P21397 5/20 0.50
PPARA Q07869 2/20 0.50
PLA2G2A P14555 1/20 0.48
XDH P47989 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658180 1.00 ALB (0.58) ALBPPARDMAOBALDH2MAOA
SCHEMBL3660001 0.94 PPARD (0.57) ALBPPARDMAOBXDH
SCHEMBL3655057 0.90 MAOB (0.50) ALBPPARDMAOBPLA2G2A
SCHEMBL10687936 0.88 PPARD (0.71) PPARDMAOBMAOA
SCHEMBL8062685 0.86 PPARD (0.56) PPARDMAOBMAOA
SCHEMBL8064850 0.86 PPARD (0.56) PPARDMAOBMAOA
SCHEMBL8064862 0.86 PPARD (0.52) PPARDMAOBMAOA
SCHEMBL3302212 0.86 PPARD (0.52) PPARDMAOB
SCHEMBL8053501 0.86 PPARD (0.56) PPARDMAOBMAOA
SCHEMBL3298167 0.86 PPARD (0.52) PPARDMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9364424-B2 Topical cosmetic skin lightening compositions and methods of use thereof STIEFEL LABORATORIES, INC. (US) 2016-06-14 US disclosed
US-20160074315-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. 2016-03-17 US disclosed
EP-2219600-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2010-08-25 EP disclosed
WO-2009067095-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2009-05-28 WO disclosed
EP-1602354-B1 Use of polyglutamic acid or its salts MEIJI SEIKA KAISHA (JP) 2008-11-05 EP disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC ALB 388/4885PPARD 1782/4885MAOB 3870/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR ALB 2719/4885PPARD 1840/4885MAOB 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.